Atkinson Edward Morrow III — SEC Form 4 filings
SEC reporting owner CIK 1914164. 22 Form 4 filings on record with FilingPulse; latest filed 2026-02-26.
Transaction summary — filings shown
Covers all 22 filings on record, filed 2024-02-05 to 2026-02-26. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 13 legs across 12 filings — 25,017 shares, $11,598,282 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 29.
- Largest priced transaction: sale of 7,288 shares @ $478.00 ($3,483,664) in VERTEX PHARMACEUTICALS INC / MA, filed 2024-06-13.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | EVP, Chief Technical Ops. Off. | 19 | — | 13 legs · 25,017 sh · $11,598,282 | 23 |
| 89bio, Inc. (ETNB) | Director | 3 | — | — | 6 |
Form 4 filings — Atkinson Edward Morrow III
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-02-26 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Tax withholding (F): 1,627 @ $485.11 · Sale (S): 668 @ $486.35 | EDGAR |
| 2026-02-19 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 4,962 @ $0 · Tax withholding (F): 1,530 @ $483.75 · Sale (S): 2,031 @ $489.46 · Sale (S): 817 @ $473.68 | EDGAR |
| 2026-02-18 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Tax withholding (F): 1,903 @ $487.76 | EDGAR |
| 2026-02-12 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Tax withholding (F): 872 @ $468.41 · Sale (S): 1,751 @ $460.43 | EDGAR |
| 2026-01-26 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 3,934 @ $0 · Grant/award (A): 3,883 @ $0 | EDGAR |
| 2025-11-19 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Sale (S): 2,500 @ $434.58 | EDGAR |
| 2025-10-30 | 4 | 89bio, Inc. (ETNB) | Disposition to issuer (D): 20,000 (derivative) @ $0 · Disposition to issuer (D): 27,400 (derivative) @ $0 · Disposition to issuer (D): 45,150 (derivative) @ $0 · Disposition to issuer (D): 56,400 (derivative) @ $0 | EDGAR |
| 2025-02-28 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Tax withholding (F): 2,482 @ $479.61 · Sale (S): 2,650 @ $475.34 | EDGAR |
| 2025-02-26 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Tax withholding (F): 1,656 @ $483.28 · Sale (S): 1,767 @ $480.95 | EDGAR |
| 2025-02-19 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Tax withholding (F): 1,529 @ $463.46 | EDGAR |
| 2025-02-14 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 6,211 @ $0 | EDGAR |
| 2025-02-12 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Tax withholding (F): 876 @ $467.98 · Sale (S): 1,747 @ $459.83 | EDGAR |
| 2025-02-06 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 5,132 @ $0 · Grant/award (A): 4,744 @ $0 | EDGAR |
| 2025-02-05 | 4 | 89bio, Inc. (ETNB) | Grant/award (A): 56,400 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Tax withholding (F): 6,824 @ $481.96 · Sale (S): 7,288 @ $478 | EDGAR |
| 2024-05-16 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 14,112 @ $0 | EDGAR |
| 2024-02-27 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Tax withholding (F): 1,654 @ $431.79 · Sale (S): 883 @ $425.70 | EDGAR |
| 2024-02-23 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Sale (S): 1,201 @ $421.77 | EDGAR |
| 2024-02-21 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Tax withholding (F): 1,501 @ $424.01 · Tax withholding (F): 1,125 @ $420.58 · Sale (S): 801 @ $420.79 | EDGAR |
| 2024-02-13 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Tax withholding (F): 832 @ $422.74 · Sale (S): 913 @ $420.24 | EDGAR |
| 2024-02-08 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 2,326 @ $0 · Grant/award (A): 3,934 @ $0 · Grant/award (A): 4,743 @ $0 | EDGAR |
| 2024-02-05 | 4 | 89bio, Inc. (ETNB) | Grant/award (A): 45,150 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1914164 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →